IQVIA Holdings Inc(IQV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 5:01 PM ET (Korea 10/27 06:01)
Full metrics table
| Index | S&P 500 | P/E | 33.94 | EPS (ttm) | 8.06 | Insider Own | 1% | Shs Outstand | 164.6M | Perf Week | 2.9% |
| Market Cap | 45.03B | Forward P/E | 19.04 | EPS next Y | 11% | Insider Trans | -6.89% | Shs Float | 163.0M | Perf Month | 1.19% |
| Enterprise Value | 59.33B | PEG | 1.81 | EPS next Q | 3.26 | Inst Own | 102.23% | Short Float | 1.97% | Perf Quarter | 12.62% |
| Income | 1.38B | P/S | 2.65 | EPS this Y | 8.59% | Inst Trans | -1.29% | Short Ratio | 2.18 | Perf Half Y | 66.99% |
| Sales | 16.99B | P/B | 7.3 | EPS next 5Y | 10.5% | ROA | 4.7% | Short Interest | 3.22M | Perf YTD | 21.38% |
| Book/sh | 37.49 | P/C | 21.65 | EPS past 3/5Y | 11.05% 40.52% | ROE | 23.01% | 52W High | -3.31% ($282.98) | Perf Year | 24.07% |
| Cash/sh | 12.64 | P/FCF | 20.62 | Sales past 3/5Y | 4.18% 7.5% | ROIC | 6.83% | 52W Low | 77.09% ($154.50) | Perf 3Y | 48.36% |
| Dividend Est. | - | EV/EBITDA | 16.73 | EPS Y/Y TTM | 16.68% | Gross Margin | 26.02% | Volatility(W/M) | 3.14% 2.93% | Perf 5Y | 6.84% |
| Dividend TTM | - | EV/Sales | 3.49 | Sales Y/Y TTM | 8.22% | Oper. Margin | 13.9% | ATR (14) | 8 | Perf 10Y | 274.18% |
| Dividend Ex-Date | - | Quick Ratio | 0.71 | EPS Q/Q | -0.36% | Profit Margin | 8.09% | RSI (14) | 57.68 | Recom | 1.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.71 | Sales Q/Q | 8.84% | SMA20 | 2.78% ($266.2) | Beta | 1.16 | Target Price | $304.71 |
| Payout | - | Debt/Eq | 2.63 | Earnings | 2026/10/27 | SMA50 | 3.65% ($263.97) | Rel Volume | 1.15 | Prev Close | $279.36 |
| Employees | 93000 | LT Debt/Eq | 2.26 | EPS/Sales Surpr. | 3.88% 1.53% | SMA200 | 30.98% ($208.89) | Avg Volume(3M) | 1.47M | Price | $273.6 |
| IPO | 2013/5/9 | Option/Short | Yes/Yes | Trades | 23092 | Volume | 1,687,876 | Change | -2.06% |
A comprehensive healthcare services company that provides global clinical trial Contract Research Organization (CRO), healthcare data, analytics, and commercialization solutions. Headquartered in Durham, North Carolina, the company combines clinical trial services with global prescription and medical data analytics through its unique business model, ranking among the top in market capitalization within the global CRO and healthcare data analytics group.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
Next earnings report: October 27
1 days to go.
IQV earns moderately but has a weak balance sheet
Of every $100 in sales, $13.90 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.6% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $1,673. Peers typically go for $2,566. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +6.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 102.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 44 in the industry
Based on market cap of $45B.
A#4 Agilent Technologies Inc $50B PER 34.6 
IQV#5 IQVIA Holdings Inc $45B PER 33.9 
IDXX#6 Idexx Laboratories Inc $45B PER 40.1 
WAT#7 Waters Corp $45B PER 113.9 
ILMN#8 Illumina Inc $41B PER 50.5 
FAQ
What kind of company is IQV?
IQV belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of IQV?
The market cap of IQV is approximately $45.0B, ranking 341 within its sector.
What is the P/E ratio of IQV?
IQV has a P/E ratio of approximately 33.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IQV?
IQV has recorded a 52-week high of $282.98 and a low of $154.50.
